Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

BACKGROUND: This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs), and determine the maximum tolerated dose (MTD) of oral TAK-285, a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322948/
https://www.ncbi.nlm.nih.gov/pubmed/22240796
http://dx.doi.org/10.1038/bjc.2011.590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322948/
https://www.ncbi.nlm.nih.gov/pubmed/22240796
http://dx.doi.org/10.1038/bjc.2011.590

Ejemplares similares